Status
Conditions
About
CLET is a published treatment for the management of corneal failure due to extensive LSCD. Due to our previous studies on this novel treatment, the regulatory agency of Spain "Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)" authorized our institution (IOBA-University of Valladolid) to perform this kind of therapy (CLET) in a case-by-case base following the Special Situation Medicines Policy Procedure in Spain. Upon approval of the permanent authorization patients will be included as specified by AEMPS.The objective of this study is to perform a protocolized treatment and follow up so that results can be reported to the scientific community.
Enrollment
Sex
Volunteers
Inclusion and exclusion criteria
Total and/or severe LSCD of any etiology in one or both eyes.
30 participants in 1 patient group
Loading...
Central trial contact
Margarita Calonge, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal